{
  "id": 19883525,
  "title": "Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?",
  "url": "https://urgent.news/2026/11/13/amgen-vs-vertex-pharmaceuticals-which-healthcare-stock-is-a-better",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T22:42:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/better-buy/2026/11/13/amgen-vs-vertex-pharmaceuticals-which-healthcare-stock-is-a-better-buy-for-2027/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "When weighing Amgen (AMGN) and Vertex Pharmaceuticals (VRTX) as potential investments for 2027, it is essential to consider their respective business models, financial health, and growth prospects.\n\nAmgen operates in the broad healthcare sector, manufacturing and distributing medicines for various serious diseases, including oncology and rare diseases. The company has a diversified customer base, primarily relying on three major distributors, and generates substantial revenue from its core portfolio. However, Amgen faces significant competition from biosimilars, generics, and pricing pressures from payers and pharmacy benefit managers, as well as regulatory risks stemming from the Inflation Reduction Act. The company's high debt-to-equity ratio of approximately 6.3x indicates a substantial level of leverage in financing its operations.\n\nOn the other hand, Vertex Pharmaceuticals specializes in transformative treatments for specific genetic conditions, such as cystic fibrosis and sickle cell disease. The company has successfully partnered with CRISPR Therapeutics (CRSP) to develop Casgevy, a promising therapy for cystic fibrosis. Vertex's revenue and net income have shown remarkable growth, reaching $13.0 billion and $4.0 billion, respectively, in the 12 months ending September 30, 2026. The company exhibits a significantly lower debt-to-equity ratio of 0.1x, providing it with financial flexibility. Its current ratio stands at approximately 2.9x, and it generated free cash flow of about $3.2 billion during the fiscal year 2025.\n\nIn terms of valuation, Amgen's lower Forward P/E and P/S ratios may make it more appealing to value-conscious investors. However, Vertex's focus on niche medical markets and its potential approval of promising therapies like Alyftrek and Povetacicept for various chronic autoimmune diseases could drive substantial future growth.\n\nGiven these factors, investors should carefully weigh the stability and diversification of Amgen against the high-growth potential of Vertex Pharmaceuticals in specific genetic therapies. Ultimately, the decision will depend on the investor's risk tolerance, growth objectives, and preference for either a diversified business model or a specialized, high-growth focus.",
  "summary": "Amgen trades at a lower forward P/E than Vertex, but Vertex's near-zero debt and cystic fibrosis dominance make the trade-off harder to call.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?",
        "url": "https://urgent.news/2026/11/13/amgen-vs-vertex-pharmaceuticals-which-healthcare-stock-is-a-better-19885714",
        "published": "2026-11-13T23:02:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}